Kazia Therapeutics Ltd
kaziatherapeutics.comWhat Do They Do?
Develops oncology drug candidates, including a treatment designed for brain cancer and another candidate for cancer indications.
20-F for FY2025, filed Nov 7, 2025The ongoing principal business of the Company has been pharmaceutical drug development. The Company is an emerging oncology-focused…View ↗
Kazia’s lead program is Paxalisib, (formerly known as GDC-0084), an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR…View ↗
Kazia is also developing EVT801, a small-molecule selective inhibitor of VEGFR3. EVT801 was originally discovered by Sanofi SA and was…View ↗
How Are They Changing?
Paxalisib expands beyond brain cancer
The older report described paxalisib development in primary and metastatic brain cancers; the latest report also describes a company-sponsored trial in advanced triple-negative breast cancer combining paxalisib with pembrolizumab and chemotherapy.
20-F for FY2022, filed Oct 17, 2022 20-F for FY2025, filed Nov 7, 2025Preclinical studies conducted in collaboration with QIMR Berghofer demonstrated that Paxalisib, exerts potent epigenetic and…View ↗
Loading...
